448 related articles for article (PubMed ID: 25863528)
21. Cellular and pathological heterogeneity of primary tauopathies.
Chung DC; Roemer S; Petrucelli L; Dickson DW
Mol Neurodegener; 2021 Aug; 16(1):57. PubMed ID: 34425874
[TBL] [Abstract][Full Text] [Related]
22. Microglial activation arises after aggregation of phosphorylated-tau in a neuron-specific P301S tauopathy mouse model.
van Olst L; Verhaege D; Franssen M; Kamermans A; Roucourt B; Carmans S; Ytebrouck E; van der Pol SMA; Wever D; Popovic M; Vandenbroucke RE; Sobrino T; Schouten M; de Vries HE
Neurobiol Aging; 2020 May; 89():89-98. PubMed ID: 32008854
[TBL] [Abstract][Full Text] [Related]
23. Tau pathology is present in vivo and develops in vitro in sensory neurons from human P301S tau transgenic mice: a system for screening drugs against tauopathies.
Mellone M; Kestoras D; Andrews MR; Dassie E; Crowther RA; Stokin GB; Tinsley J; Horne G; Goedert M; Tolkovsky AM; Spillantini MG
J Neurosci; 2013 Nov; 33(46):18175-89. PubMed ID: 24227726
[TBL] [Abstract][Full Text] [Related]
24. GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils.
Gibbons GS; Banks RA; Kim B; Xu H; Changolkar L; Leight SN; Riddle DM; Li C; Gathagan RJ; Brown HJ; Zhang B; Trojanowski JQ; Lee VM
J Neurosci; 2017 Nov; 37(47):11485-11494. PubMed ID: 28986461
[TBL] [Abstract][Full Text] [Related]
25. Tau mis-splicing correlates with motor impairments and striatal dysfunction in a model of tauopathy.
Damianich A; Facal CL; Muñiz JA; Mininni C; Soiza-Reilly M; Ponce De León M; Urrutia L; Falasco G; Ferrario JE; Avale ME
Brain; 2021 Sep; 144(8):2302-2309. PubMed ID: 34059893
[TBL] [Abstract][Full Text] [Related]
26. Oligodendrogenesis increases in hippocampal grey and white matter prior to locomotor or memory impairment in an adult mouse model of tauopathy.
Ferreira S; Pitman KA; Summers BS; Wang S; Young KM; Cullen CL
Eur J Neurosci; 2021 Sep; 54(5):5762-5784. PubMed ID: 32181929
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenetic neuronal stimulation increases human tau pathology and trans-synaptic spread of tau to distal brain regions in mice.
Schultz MK; Gentzel R; Usenovic M; Gretzula C; Ware C; Parmentier-Batteur S; Schachter JB; Zariwala HA
Neurobiol Dis; 2018 Oct; 118():161-176. PubMed ID: 30049665
[TBL] [Abstract][Full Text] [Related]
28. Triggering receptor expressed on myeloid cells 2 deficiency exacerbates injury-induced inflammation in a mouse model of tauopathy.
Katsumoto A; Kokiko-Cochran ON; Bemiller SM; Xu G; Ransohoff RM; Lamb BT
Front Immunol; 2022; 13():978423. PubMed ID: 36389767
[TBL] [Abstract][Full Text] [Related]
29. Developmental exposure to lead (Pb) alters the expression of the human tau gene and its products in a transgenic animal model.
Dash M; Eid A; Subaiea G; Chang J; Deeb R; Masoud A; Renehan WE; Adem A; Zawia NH
Neurotoxicology; 2016 Jul; 55():154-159. PubMed ID: 27293183
[TBL] [Abstract][Full Text] [Related]
30. The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy.
Hansen HH; Barkholt P; Fabricius K; Jelsing J; Terwel D; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Mar; 1634():158-170. PubMed ID: 26746341
[TBL] [Abstract][Full Text] [Related]
31. Plasma MicroRNAs Are Altered Early and Consistently in a Mouse Model of Tauopathy.
Ryan B; Williams JM; Curtis MA
Neuroscience; 2019 Jul; 411():164-176. PubMed ID: 31152932
[TBL] [Abstract][Full Text] [Related]
32. Genetic forms of tauopathies: inherited causes and implications of Alzheimer's disease-like TAU pathology in primary and secondary tauopathies.
Langerscheidt F; Wied T; Al Kabbani MA; van Eimeren T; Wunderlich G; Zempel H
J Neurol; 2024 Jun; 271(6):2992-3018. PubMed ID: 38554150
[TBL] [Abstract][Full Text] [Related]
33. Kinase activities increase during the development of tauopathy in htau mice.
Kelleher I; Garwood C; Hanger DP; Anderton BH; Noble W
J Neurochem; 2007 Dec; 103(6):2256-67. PubMed ID: 17908241
[TBL] [Abstract][Full Text] [Related]
34. Familial globular glial tauopathy linked to MAPT mutations: molecular neuropathology and seeding capacity of a prototypical mixed neuronal and glial tauopathy.
Ferrer I; Andrés-Benito P; Zelaya MV; Aguirre MEE; Carmona M; Ausín K; Lachén-Montes M; Fernández-Irigoyen J; Santamaría E; Del Rio JA
Acta Neuropathol; 2020 Apr; 139(4):735-771. PubMed ID: 31907603
[TBL] [Abstract][Full Text] [Related]
35. Tau reduction with artificial microRNAs modulates neuronal physiology and improves tauopathy phenotypes in mice.
Facal CL; Fernández Bessone I; Muñiz JA; Pereyra AE; Pedroncini O; Páez-Paz I; Clerici-Delville R; Arnaiz C; Urrutia L; Falasco G; Argañaraz CV; Saez T; Marin-Burgin A; Soiza-Reilly M; Falzone T; Avale ME
Mol Ther; 2024 Apr; 32(4):1080-1095. PubMed ID: 38310353
[TBL] [Abstract][Full Text] [Related]
36. Knock-out and transgenic mouse models of tauopathies.
Denk F; Wade-Martins R
Neurobiol Aging; 2009 Jan; 30(1):1-13. PubMed ID: 17590238
[TBL] [Abstract][Full Text] [Related]
37. The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy.
Mocanu MM; Nissen A; Eckermann K; Khlistunova I; Biernat J; Drexler D; Petrova O; Schönig K; Bujard H; Mandelkow E; Zhou L; Rune G; Mandelkow EM
J Neurosci; 2008 Jan; 28(3):737-48. PubMed ID: 18199773
[TBL] [Abstract][Full Text] [Related]
38. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
Stancu IC; Ferraiolo M; Terwel D; Dewachter I
Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
[TBL] [Abstract][Full Text] [Related]
39. Increased 4R tau expression and behavioural changes in a novel MAPT-N296H genomic mouse model of tauopathy.
Wobst HJ; Denk F; Oliver PL; Livieratos A; Taylor TN; Knudsen MH; Bengoa-Vergniory N; Bannerman D; Wade-Martins R
Sci Rep; 2017 Feb; 7():43198. PubMed ID: 28233851
[TBL] [Abstract][Full Text] [Related]
40. Picalm reduction exacerbates tau pathology in a murine tauopathy model.
Ando K; De Decker R; Vergara C; Yilmaz Z; Mansour S; Suain V; Sleegers K; de Fisenne MA; Houben S; Potier MC; Duyckaerts C; Watanabe T; Buée L; Leroy K; Brion JP
Acta Neuropathol; 2020 Apr; 139(4):773-789. PubMed ID: 31925534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
